Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide

J. Hoefer, M. Akbor, F. Handle, P. Ofer, M. Puhr, W. Parson, Z. Culig, H. Klocker, I. Heidegger,

. 2016 ; 7 (37) : 59781-59794.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18011087

Enzalutamide is an androgen receptor (AR) inhibitor approved for therapy of metastatic castration resistant prostate cancer. However, clinical application revealed that 30 to 40% of patients acquire resistance after a short period of treatment. Currently, the molecular mechanisms underlying such resistances are not completely understood, partly due to a lack of model systems. In the present study we established three different cellular models of enzalutamide resistance including a cell line with wild type AR (LAPC4), DuCaP cells which overexpress wild-type AR, as well as a cell which has been adapted to long term androgen ablation (LNCaP Abl) and harbors the AR T878A mutation. After 10 months of cultivation, sustained growth in the presence of enzalutamide was achieved. When compared to controls, resistant cells exhibit significantly decreased sensitivity to enzalutamide as measured with 3[H]thymidine incorporation and WST assay. Moreover, these cell models exhibit partly re-activated AR signaling despite presence of enzalutamide. In addition, we show that enzalutamide resistant cells are insensitive to bicalutamide but retain considerable sensitivity to abiraterone. Mechanistically, enzalutamide resistance was accompanied by increased AR and AR-V7 mRNA and protein expression as well as AR gene amplification, while no additional AR mutations have been identified.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011087
003      
CZ-PrNML
005      
20180404142533.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.10926 $2 doi
035    __
$a (PubMed)27486973
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hoefer, Julia $u Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria.
245    10
$a Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide / $c J. Hoefer, M. Akbor, F. Handle, P. Ofer, M. Puhr, W. Parson, Z. Culig, H. Klocker, I. Heidegger,
520    9_
$a Enzalutamide is an androgen receptor (AR) inhibitor approved for therapy of metastatic castration resistant prostate cancer. However, clinical application revealed that 30 to 40% of patients acquire resistance after a short period of treatment. Currently, the molecular mechanisms underlying such resistances are not completely understood, partly due to a lack of model systems. In the present study we established three different cellular models of enzalutamide resistance including a cell line with wild type AR (LAPC4), DuCaP cells which overexpress wild-type AR, as well as a cell which has been adapted to long term androgen ablation (LNCaP Abl) and harbors the AR T878A mutation. After 10 months of cultivation, sustained growth in the presence of enzalutamide was achieved. When compared to controls, resistant cells exhibit significantly decreased sensitivity to enzalutamide as measured with 3[H]thymidine incorporation and WST assay. Moreover, these cell models exhibit partly re-activated AR signaling despite presence of enzalutamide. In addition, we show that enzalutamide resistant cells are insensitive to bicalutamide but retain considerable sensitivity to abiraterone. Mechanistically, enzalutamide resistance was accompanied by increased AR and AR-V7 mRNA and protein expression as well as AR gene amplification, while no additional AR mutations have been identified.
650    _2
$a androsteny $x farmakologie $7 D000736
650    _2
$a anilidy $x farmakologie $7 D000813
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $x genetika $7 D049109
650    _2
$a viabilita buněk $x účinky léků $x genetika $7 D002470
650    _2
$a chemorezistence $x účinky léků $x genetika $7 D019008
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a nitrily $x farmakologie $7 D009570
650    _2
$a fenylthiohydantoin $x analogy a deriváty $x farmakologie $7 D010669
650    _2
$a nádory prostaty $x genetika $x metabolismus $x patologie $7 D011471
650    _2
$a androgenní receptory $x genetika $x metabolismus $7 D011944
650    _2
$a signální transdukce $x účinky léků $x genetika $7 D015398
650    _2
$a tosylové sloučeniny $x farmakologie $7 D014105
655    _2
$a časopisecké články $7 D016428
700    1_
$a Akbor, Mohammady $u Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria. School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.
700    1_
$a Handle, Florian $u Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria.
700    1_
$a Ofer, Philipp $u Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria.
700    1_
$a Puhr, Martin $u Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria.
700    1_
$a Parson, Walther $u Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria. Forensic Science Program, The Pennsylvania State University, University Park, Pennsylvania, USA.
700    1_
$a Culig, Zoran $u Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's Hospital, Brno, Czech Republic.
700    1_
$a Klocker, Helmut $u Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria.
700    1_
$a Heidegger, Isabel $u Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 37 (2016), s. 59781-59794
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27486973 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142612 $b ABA008
999    __
$a ok $b bmc $g 1288572 $s 1007899
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 37 $d 59781-59794 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options